Products
Pipeline
Antisoma clinical development pipeline
| Drug | Indication | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|
| AS1413 | Secondary AML | ||||
| AS1411 | AML | ||||
| DCAM's | Auto-immune |
AS1413 (amonafide L-malate) is a DNA intercalator in phase III in secondary AML
AS1411 is a DNA aptamer in phase II in AML
DCAMs are inhibitors of wild-type Flt-3 and are being developed for auto-immune diseases
Back to top